{"id":"talazoparib-plus-enzalutamide","safety":{"commonSideEffects":[{"effect":"Anaemia","drugRate":"52.8%","placeboRate":"","totalAtRisk":127,"totalAffected":67,"trialsReporting":1},{"effect":"Nausea","drugRate":"35.4%","placeboRate":"","totalAtRisk":127,"totalAffected":45,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"29.9%","placeboRate":"","totalAtRisk":127,"totalAffected":38,"trialsReporting":1},{"effect":"Asthenia","drugRate":"25.2%","placeboRate":"","totalAtRisk":127,"totalAffected":32,"trialsReporting":1},{"effect":"Fatigue","drugRate":"22.0%","placeboRate":"","totalAtRisk":127,"totalAffected":28,"trialsReporting":1},{"effect":"Constipation","drugRate":"21.3%","placeboRate":"","totalAtRisk":127,"totalAffected":27,"trialsReporting":1},{"effect":"Platelet count decreased","drugRate":"21.3%","placeboRate":"","totalAtRisk":127,"totalAffected":27,"trialsReporting":1},{"effect":"Oedema peripheral","drugRate":"18.1%","placeboRate":"","totalAtRisk":127,"totalAffected":23,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"17.3%","placeboRate":"","totalAtRisk":127,"totalAffected":22,"trialsReporting":1},{"effect":"Neutrophil count decreased","drugRate":"17.3%","placeboRate":"","totalAtRisk":127,"totalAffected":22,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"15.0%","placeboRate":"","totalAtRisk":127,"totalAffected":19,"trialsReporting":1},{"effect":"Back pain","drugRate":"15.0%","placeboRate":"","totalAtRisk":127,"totalAffected":19,"trialsReporting":1},{"effect":"Dyspnoea","drugRate":"13.4%","placeboRate":"","totalAtRisk":127,"totalAffected":17,"trialsReporting":1},{"effect":"Vomiting","drugRate":"12.6%","placeboRate":"","totalAtRisk":127,"totalAffected":16,"trialsReporting":1},{"effect":"Dizziness","drugRate":"11.8%","placeboRate":"","totalAtRisk":127,"totalAffected":15,"trialsReporting":1},{"effect":"White blood cell count decreased","drugRate":"10.2%","placeboRate":"","totalAtRisk":127,"totalAffected":13,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"10.2%","placeboRate":"","totalAtRisk":127,"totalAffected":13,"trialsReporting":1},{"effect":"Hot flush","drugRate":"9.4%","placeboRate":"","totalAtRisk":127,"totalAffected":12,"trialsReporting":1},{"effect":"Lymphocyte count decreased","drugRate":"8.7%","placeboRate":"","totalAtRisk":127,"totalAffected":11,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"7.9%","placeboRate":"","totalAtRisk":127,"totalAffected":10,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"7.9%","placeboRate":"","totalAtRisk":127,"totalAffected":10,"trialsReporting":1},{"effect":"Cough","drugRate":"7.9%","placeboRate":"","totalAtRisk":127,"totalAffected":10,"trialsReporting":1},{"effect":"Chest pain","drugRate":"7.1%","placeboRate":"","totalAtRisk":127,"totalAffected":9,"trialsReporting":1},{"effect":"Fall","drugRate":"7.1%","placeboRate":"","totalAtRisk":127,"totalAffected":9,"trialsReporting":1},{"effect":"Bone pain","drugRate":"7.1%","placeboRate":"","totalAtRisk":127,"totalAffected":9,"trialsReporting":1},{"effect":"Headache","drugRate":"7.1%","placeboRate":"","totalAtRisk":127,"totalAffected":9,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"6.3%","placeboRate":"","totalAtRisk":127,"totalAffected":8,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"6.3%","placeboRate":"","totalAtRisk":127,"totalAffected":8,"trialsReporting":1},{"effect":"Dysgeusia","drugRate":"6.3%","placeboRate":"","totalAtRisk":127,"totalAffected":8,"trialsReporting":1},{"effect":"Paraesthesia","drugRate":"6.3%","placeboRate":"","totalAtRisk":127,"totalAffected":8,"trialsReporting":1},{"effect":"Insomnia","drugRate":"6.3%","placeboRate":"","totalAtRisk":127,"totalAffected":8,"trialsReporting":1},{"effect":"Haematuria","drugRate":"6.3%","placeboRate":"","totalAtRisk":127,"totalAffected":8,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"5.5%","placeboRate":"","totalAtRisk":127,"totalAffected":7,"trialsReporting":1},{"effect":"Weight decreased","drugRate":"5.5%","placeboRate":"","totalAtRisk":127,"totalAffected":7,"trialsReporting":1},{"effect":"Hypertension","drugRate":"5.5%","placeboRate":"","totalAtRisk":127,"totalAffected":7,"trialsReporting":1}]},"_chembl":null,"_fixedAt":"2026-03-30T11:32:05.987138","allNames":"talazoparib plus enzalutamide","_dailymed":null,"mechanism":{"target":"PARP, AR","drugClass":"PARP inhibitor, androgen receptor inhibitor","explanation":"Talazoparib blocks the PARP enzyme, preventing DNA repair, while enzalutamide inhibits the androgen receptor, reducing tumor growth signals. Together, they increase DNA damage and decrease survival of cancer cells.","oneSentence":"Talazoparib and enzalutamide work synergistically to inhibit PARP and androgen receptor pathways, respectively, leading to enhanced DNA damage and reduced tumor growth in prostate cancer cells."},"_scrapedAt":"2026-03-28T00:43:53.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"revenueYear":2025,"annualRevenue":2194,"revenueSource":"SEC 8-K Pfizer (2026-02-03)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:46:15.552584","revenueExtractedBy":"revenue-sec"},"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:37:27.629922+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT03395197","phase":"PHASE3","title":"Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2017-12-18","conditions":"mCRPC","enrollment":1054},{"nctId":"NCT04821622","phase":"PHASE3","title":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-05-12","conditions":"Prostate Cancer","enrollment":599},{"nctId":"NCT05873192","phase":"PHASE2","title":"Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-06-03","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT06844383","phase":"PHASE2","title":"A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate","status":"RECRUITING","sponsor":"Prostate Cancer Clinical Trials Consortium","startDate":"2025-10","conditions":"Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)","enrollment":126},{"nctId":"NCT06168487","phase":"PHASE1","title":"Telmisartan in Prostate Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2024-04-22","conditions":"Prostate Cancer","enrollment":36},{"nctId":"NCT04332744","phase":"PHASE2","title":"Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-09-02","conditions":"Metastatic Prostate Cancer","enrollment":54},{"nctId":"NCT06582628","phase":"PHASE2","title":"Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)","status":"RECRUITING","sponsor":"Fundacion Oncosur","startDate":"2024-07-05","conditions":"Metastatic Prostate Cancer","enrollment":78},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT03148795","phase":"PHASE2","title":"A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-04","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT05406999","phase":"PHASE2","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-02-01","conditions":"Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer","enrollment":900},{"nctId":"NCT04052204","phase":"PHASE1, PHASE2","title":"Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"_revenueScrapedAt":"2026-04-01 10:46:15.582442+00","recentPublications":[{"date":"2025 Oct","pmid":"41116982","title":"Patient-related reported outcomes (PROs) from TALAPRO-2: the PROs and cons.","journal":"Chinese clinical oncology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"talazoparib plus enzalutamide","genericName":"talazoparib-plus-enzalutamide","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:37:27.629922+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}